NANOBIOTIX Announces Four Presentations at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
The Pharma Data
OCTOBER 19, 2020
In the United States, the Company has started the regulatory process to commence a phase III clinical trial in locally advanced head and neck cancers. The Company is also engaged in a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to further expand the NBTXR3 development program.
Let's personalize your content